Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy 23andMe (ME) shares

Learn how to easily invest in 23andMe shares.

23andMe is a diagnostics & research business based in the US. 23andMe stocks (ME.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $10.63 – a decrease of 8.52% over the previous week. 23andMe employs 0 staff and has a trailing 12-month revenue of around $258.5 million.

How to buy shares in 23andMe

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ME – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

23andMe stock price (NASDAQ:ME)

Use our graph to track the performance of ME stocks over time.

23andMe shares at a glance

Information last updated 2022-01-22.
Latest market close$4.40
52-week range$4.40 - $18.16
50-day moving average $7.86
200-day moving average $9.25
Wall St. target price$11.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.21

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy 23andMe stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

23andMe price performance over time

Historical closes compared with the close of $4.4 from 2022-01-25

1 week (2022-01-20) -5.38%
1 month (2021-12-27) -35.10%
3 months (2021-10-27) -64.52%
6 months (2021-07-27) -46.86%
1 year (2021-01-27) -67.53%
2 years (2020-01-23) N/A
3 years (2019-01-23) N/A
5 years (2017-01-23) N/A

23andMe financials

Revenue TTM $258.5 million
Gross profit TTM $117 million
Return on assets TTM -24.26%
Return on equity TTM -111.99%
Profit margin -65.84%
Book value $1.62
Market capitalisation $2.1 billion

TTM: trailing 12 months

23andMe share dividends

We're not expecting 23andMe to pay a dividend over the next 12 months.

23andMe overview

23andMe Holding Co. operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited to leverage genetic insights to validate, develop, and commercialize promising drugs. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site